

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Prior Application Number	09/953,933 10/602,617
			Prior Appl. Filing Date	09/16/2001
Date Submitted: (use as many sheets as necessary)			First Named Inventor	Hui Chen
			Group Art Unit	Unassigned 1626
Sheet 1 of 8			Examiner Name	Unassigned E. Sackey
			Attorney Docket Number	038602-1585

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
E	A1	08/179570		HIRTH et al.		
	A2	3,313,771		DRESSLER et al.	04-11-1967	
	A3	5,217,999	A	LEVITZKI et al.	06-08-1993	
	A4	5,302,606	A	SPADA et al.	04-12-1994	
	A5	5,439,895	A	LEE et al.	08-08-1995	
	A6	5,656,643	A	SPADA et al.	08-12-1997	
	A7	5,700,823	A	HIRTH et al.	12-23-1997	
E	A8	5,712,395	A	APP et al.	07-27-1998	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
ES	A9	AU	31010/93	A	Barker	07-22-1993		
	A10	CA	2,069,857	A1	CIBA-GEIGY AG	12-01-1992		
	A11	CA	2,086,968	A1	ZENECA LIMITED	06-23-1998		
	A12	EP	0 520 722	A1	ZENECA LIMITED	12-27-1996		
	A13	EP	0 537 742	B1	MITSUBISHI CHEMICAL CORPORATION	08-21-1996		
	A14	EP	0 566 226	B1	ZENECA LIMITED	11-08-1995		
	A15	GB	1,191,306		KOPPERS COMPANY	05-13-1970		
ES	A16	GB	2,240,104	A	FARMATALIA CARLO ERBA S.r.l.	07-24-1991		

Examiner Signature	<i>Edward Sackey</i>	Date Considered	6/7/05
-----------------------	----------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
				Prior Application Number	09/953,933 10/602,617
				Prior Appl. Filing Date	09/18/2001
				First Named Inventor	Hui Chen
				Group Art Unit	Unassigned 1626
				Examiner Name	Unassigned E. Sackey
Sheet 2 of 8				Attorney Docket Number	038602-1585

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
ES	A17	WO	92/02444	A1	THE DOW CHEMICAL COMPANY	02-20-1992		
	A18	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL, INC.	11-26-1992		
	A19	WO	92/21641	A1	PFIZER INC.	12-10-1992		
	A20	WO	94/24095	A1	ABBOTT LABORATORIES	10-27-1997		
	A21	WO	94/26260	A1	YISSUM-RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	11-24-1994		
ES	A22	WO	95/24190	A2	SUGEN, INC. et al.	09-14-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>6</sup>
ES	A23	AARONSON, S., "Growth Factors and Cancer," <u>Science</u> 254:1146-1153 (1991)						
	A24	AFFLECK et al., <u>Proc. Annu. Meeting American Association Cancer Research</u> 34:A2298 (1993)						
	A25	ANAFI et al., "Selective Interactions of Transforming and Normal abl Proteins with ATP, Tyrosine-Copolymer Substrates, and Tyrophostins," <u>J. Bio. Chem.</u> 267:4518-4523 (1992)						
	A26	ANDREWS et al. (American Veterinary Medicine Association Panel on Euthanasia), "1993 Report of the AVMA Panel on Euthanasia," <u>J. American Veterinary Medicine Association</u> 202(2):229-249 (1993)						
	A27	BASELGA et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," <u>J. of Natl. Cancer Institute</u> 85(16):1327-1333 (1993)						
ES	A28	BILDER et al., "Tyrophostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," <u>Am. J. Physiol.</u> 260 (Cell Physiol.29):C721-C730 (1991)						

Examiner Signature	<i>E. Sackey</i>	Date Considered	6/7/05
--------------------	------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Prior Application Number	09/953,933 10/602,617
		Prior Appl. Filing Date	09/18/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Hui Chen
		Group Art Unit	Unassigned 1626
Sheet 3 of 8		Examiner Name	Unassigned E. Sackley
		Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
E	A29	BIRCHALL et al., "Compositions for killing internal parasites containing 3-terti-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," <u>Chemical Abstracts</u> 88:535 (1978)	
	A30	BRYCKAERT et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," <u>Exp. Cell Research</u> 199:255-261 (1992)	
	A31	CARAGLIA et al., "Cytosine Arabinoside Increases the Binding of 125I-Labelled Eipdermal Growth Factor and 125I-Transferrin and Enhances the In Vitro Targeting of Human Tumour Cells With Anti- (Growth Factor Receptor) mAb," <u>Cancer Immunol Immunother</u> 37:150-156, (1993)	
	A32	CARBONI et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," <u>J. Am. Chem. Soc.</u> 80:2838-2840 (1958)	
	A33	CARRAWAY and CANTLEY, "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Hereodimerization in Growth Signaling," <u>Cell</u> 78:5-8 (1994)	
	A34	CARRAWAY et al., "The erbB3 Gene Product Is a Receptor for Heregulin," <u>J. Biol. Chem.</u> 269:14303-14306 (1994)	
	A35	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)	
	A36	DECKER and LOHMANN-MATTHES, "A Quick and Simple Method for the Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity," <u>J. Immunol. Methods</u> 115:61 (1988)	
	A37	DOUGALL et al., "The Neu-Oncogene: Signal Transduction Pathways, Transformation Mechanisms and Evolving Therapies," <u>Oncogene</u> 9:2109, (1994)	
	A38	FERRIS et al., "Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilnitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <u>J. Org. Chem.</u> 44(2):173-178 (1979)	
	A39	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43S:47-54 (1993)	
	A40	GAZIT et al., "Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Med. Chem.</u> 32:2344-2352 (1989)	
E	A41	GAZIT et al., "Tyrphostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991)	

Examiner Signature	<i>E. Sackley</i>	Date Considered	6/2/05
--------------------	-------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Compleat, if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Prior Application Number	09/953,933 101 602,617
		Prior Appl. Filing Date	09/18/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Hui Chen
		Group Art Unit	Unassigned 1626
Sheet 4 of 8		Examiner Name	Unassigned E. Sackey
		Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
E	A42	GAZIT et al., "Tyrophostins. 3. Structure-Activity Relationship Studies of a $\alpha$ -Substituted Benzylidenemalononitrile 5-S-Aryltyrophostins" <u>J. Med. Chem.</u> 36:3556-3564 (1993)	
	A43	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):331-314 (1988)	
	A44	GRANTHAM, F.H., "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Instit.</u> 67:51-56, (1981)	
	A45	HALE et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," <u>J. Clin. Pathol.</u> 46:149-153 (1993)	
	A46	HARRIS et al., "Breast Cancer (First of Three Parts)," <u>New England J. of Medicine</u> 327(5):319-328 (1992)	
	A47	HOEKSTRA et al., "Differential effects of steurosporine and tyrophostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," <u>Experimental Therapeutics</u> from 84 <sup>th</sup> Annual Meeting of American Association for Cancer Research, Vol. 34, #2455 (1993)	
	A48	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)	
	A49	HUDZIAK et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor," <u>Molecular and Cellular Biology</u> 9:1165-1172 (1989)	
	A50	ISSIDORIDES and HADDADIN, "Benzofurazan Oxide. II. Reactions with Enolate Anions," <u>J. Org. Chem.</u> 31:4067-4068 (1966)	
	A51	KARAMERIS et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas," <u>Path. Res. Pract.</u> 189:133-137, (1993)	
	A52	KAUR et al., "Tyrophostin induced growth inhibition: correlation with effect on p210 <sup>bcr-abl</sup> autokinase activity in K562 chronic myelogenous leukemia," <u>Anti-Cancer Drugs</u> , 1994, pp. 213-222, Vol. 5, © Rapid Communications of Oxford Ltd.	
	A53	KOENDERS et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," <u>Breast Cancer Research and Treatment</u> 25:21-27 (1993)	
E	A54	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313 (1983)	

Examiner Signature: <u>E. Sackey</u>	Date Considered: <u>6/7/05</u>
--------------------------------------	--------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted:  (use as many sheets as necessary)		Prior Application Number	09/953,933 10/602,617
		Prior Appl. Filing Date	09/18/2001
		First Named Inventor	Hui Chen
		Group Art Unit	Unassigned 1636
		Examiner Name	Unassigned E. Sackey
Sheet	5	of	8
		Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
ES	A55	LEE and SALEMNICK, "Purine N-Oxides, LXII. 2,4-Dioxypyrido[2,3-d]pyrimidine N-Oxides," <u>J. Org. Chem.</u> 40(24):3608-3610 (1975).	
	A56	LEVITZKI, A., "Tyrophostins - Potential Antiproliferative Agents and Novel Molecular Tools," <u>Biochem. Pharm.</u> 40(5):913-918 (1990)	
	A57	LEY and SENG, "Synthesen unter Verwendung von Benzofuroxan," <u>Synthesis</u> 1975:415-422 (1975)	
	A58	LOTTA, T. et al., <u>Journal of Computer-Aided Molecular Design</u> 6:253-272 (1992).	
	A59	LYALL et al., "Tyrophostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <u>J. Bio. Chem.</u> 264:14503-14509 (1989)	
	A60	MARSHALL, E., "Search for a Killer: Focus Shifts from Fat to Hormones," <u>Science</u> 259:618-621 (1993)	
	A61	MITUS and ROSENTHAL, "Ch. 30 - Adult Leukemias," <u>Textbook of Clinical Oncology</u> , Holleb, Fink and Murphy eds., pp. 410-432.	
	A62	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay," <u>J. Immunol. Methods</u> 65:55-63 (1983)	
	A63	OHMACHI et al., "The Tyrosine Kinase Inhibitor Tyrophostin Blocks the Cellular Actions of Nerve Growth Factor," <u>Biochemistry</u> 32:4650-4658 (1993)	
	A64	O'ROURKE and KALTER, "Ch. 28-Leukemia," <u>Clinical Oncology</u> , Weiss et al. eds. Norwalk Conn.	
	A65	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)	
	A66	OSHEROV et al., "Selective Inhibition of the EGF and Neu receptors by Tyrophostins," <u>J. Cell Biochem.</u> S17A:237 (1993)	
	A67	OSHEROV et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tyrophostins," <u>J. Bio. Chem.</u> 268:11134-11142 (1993)	
	A68	OZZELLO, I. and SORDAT, M., "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)	
ES	A69	PAWSON and SCHLESSINGER, "SH2 and SH3 domains," <u>Current Biology</u> 3(7):434-441 (1993)	

Examiner Signature	<i>E. Sackey</i>	Date Considered	6/7/05
--------------------	------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Prior Application Number	09/953,933 10/662,617
		Prior Appl. Filing Date	09/18/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Hui Chen
		Group Art Unit	Unassigned 1626
Sheet 6 of 8		Examiner Name	Unassigned E. Sackey
		Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
ES	A70	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <u>The Prostate</u> 22:335-345 (1993)	
	A71	PIGOTT et al., "Expression of epidermal growth factor receptor in human glioblastoma multiforme," <u>Brit. J. of Neurosurgery</u> 7:261-265 (1993)	
	A72	PLOWMAN et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> ," <u>Nature</u> 366:473-475 (1993)	
	A73	PUJ and RIVERA, "Ch. 31 - Childhood Leukemias," <u>Textbook of Clinical Oncology</u> , Holleb, Fink and Murphy eds., pp. 433-452	
	A74	REDDY et al., "Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor," <u>Cancer Research</u> 52:3636-3641 (1992)	
	A75	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <u>Biochem. Pharm.</u> 44(5):881-888 (1992)	
	A76	RUBENS, "Improving Treatment for Advanced Breast Cancer," <u>Cancer Surveys</u> 18:199-209 (1993)	
	A77	RUSCH et al., "Differential Expression of the Epidermal Growth-Factor Receptor and Its Ligands in Primary Non-Small Cell Lung Cancers and Adjacent Benign Lung," <u>Cancer Research</u> 53:2379-2385 (1993)	
	A78	RYGAARD, J. and POVLSEN, C.O., "Heterotransplantation of a Human Malignant Tumor to "Nude" Mice," <u>Acta Pathol. Microbiol. Scand.</u> 77:758-760 (1969)	
	A79	SAMANTA, "Ligand and p185 <sup>c-neu</sup> density govern receptor interactions and tyrosine kinase activation," <u>Proc. Natl. Acad. Sci. USA</u> 91:1711-1715 (1994)	
	A80	SAMMES, et al., "α-Cyano-Sulphonyl Chlorides: Their Preparation and reactions with Amines, Alcohols, and Enamines," <u>J. Chem. Soc. (C)</u> , 2151 (1971)	
	A81	SARUP, "Characterization of an Anti-p185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth," <u>Growth Regulation</u> 1:72-82 (1991)	
	A82	SCHLESSINGER, "Signal Transduction by Allosteric Receptor Oligomerization," <u>J. Trends Biochem. Sci.</u> 13:443-447, (1988)	
ES	A83	SCHLESSINGER, J. and ULLRICH, A., "Growth Factor Signaling by Receptor Tyrosine Kinases," <u>Neuron</u> 9(3):383-391, (1992)	

Examiner Signature	<i>E. Sackey</i>	Date Considered	6/7/05
--------------------	------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST: 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Prior Application Number	09/933,933 10/602,617
		Prior Appl. Filing Date	09/18/2001
Date Submitted: (use as many sheets as necessary)		First Named Inventor	Hui Chen
		Group Art Unit	Unassigned 1636
Sheet 7 of 8		Examiner Name	Unassigned E. Sackley
		Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
E	A84	SCHORNAGEL et al., "Synthesis and Evaluation of 2,4-Diaminoquinazoline Antifolates with Activity Against Methotrexate-Resistant Human Tumor Cells," <u>Biochem. Pharm.</u> 33(20):3251-3255 (1984)	
	A85	SCOTT et al., "p185 <sup>HER2</sup> Signal Transduction in Breast Cancer Cells," <u>J. Bio. Chem.</u> 266(22):14300-14305 (1991)	
	A86	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)	
	A87	SHAFIE and GRANTHAM, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl Cancer Institute</u> 67(1):51-56 (1981)	
	A88	SHEPARD, "Monoclonal Antibody Therapy of Human Cancer: taking the HER2 Protooncogene to the Clinic," <u>Journal of Clinical Immunology</u> 11:117-126 (1991)	
	A89	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)	
	A90	SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," <u>Science</u> 235:177-185 (1987)	
	A91	SLIWKOWSKI et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin," <u>J. Biol. Chem.</u> 269:14661-14665 (1994)	
	A92	STEIN et al., "The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer," <u>EMBO Journal</u> 13(6):1331-1340 (1994)	
	A93	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203, (1990)	
	A94	WADA et al., "Anti-receptor Antibodies Reverse the Phenotype of Cells Transformed by Two Interacting Proto-Oncogene Encoded Receptor Proteins," <u>Oncogene</u> 5:489-495, (1990)	
	A95	WADA et al., "Intermolecular Association of the p185neu Protein and EGF Receptor Modulates EGF Receptor Function," <u>Cell</u> 61:1339, (1990)	
E	A96	WARRI, A.M., et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," <u>Int. J. Cancer</u> , 49:616-623, (1991)	

Examiner Signature	<i>E. Sackley</i>	Date Considered	6/7/05
--------------------	-------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted:

(use as many sheets as necessary)

Sheet

8

of

8

**Complete if Known**

Prior Application Number	-00/953,933
--------------------------	-------------

Prior Appl. Filing Date	09/18/2001
-------------------------	------------

First Name of Inventor	Hui Chen
------------------------	----------

Group Art Unit	Unassigned
----------------	------------

Examiner Name	Unassigned
---------------	------------

Attorney Docket Number	038602-1585
------------------------	-------------

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner  
Signature

Broschbacher

Date Considered

6/7/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

\*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>a</sup>Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.